Open access peer-reviewed Edited Volume

Rare Diseases

Mani T. Valarmathi

The University of Alabama at Birmingham

Dr. Mani T. Valarmathi has had extensive experience in research on various types of stem cells. He is a member of the Society for Stem Cell Research, American Association for Cancer Research, American Society for Investigative Pathology, American Chemical Society, European Society of Cardiology, American Society of Gene & Cell Therapy, American Heart Association.

Covering

Rare Disease Pathophysiology Rare Disease Etiology Rare Disease Genomics Rare Disease Proteomics Rare Disease Immunology Rare Disease Immunotherapy Rare Disease Drug Discovery Rare Disease Models Rare Disease and Regenerative Medicine Rare Disease and Stem Cells Bioengineering Models of Genetic & Rare Diseases Nanomedicine of Genetic & Rare Diseases

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

A rare disease is any disease or condition that affects a small percentage of the population. In the United States alone, over 7000 rare diseases affect more than thirty million people. Many rare conditions are not only life-threatening or chronically debilitating diseases but most do not have appropriate treatments, rendering them incurable. Consequently, drug, biologic, and device development in the case of rare diseases is challenging for many reasons, including the complex biology and the lack of critical understanding of the natural course of many rare diseases. In addition, the inherently fewer population of patients with a rare disease can also make conducting clinical trials difficult. Scientists and clinicians around the globe are working to find better ways to prevent, detect, and treat a rare disease, and to improve the quality of life of patients. In recent years, there is a substantial amount of development in the area of rare disease research and its clinical applications, for instance, rare disease biology and genomics, epidemiology and preventions; early detection and screening; as well as diagnosis and treatment. Besides, since the advent of various emerging technologies, such as genome editing technology, stem cell technology, bionanotechnology, as well as regenerative medicine-and the integrated knowledge gained from such studies, not only enhancing our understanding of rare disease but also producing novel insights that could lead to the development and timely deployment of novel clinical/therapeutic interventions.

In this context, the objective of this book will be to consolidate the recent advances in the area of rare disease biology/therapeutics covering a wide spectrum of interrelated topics in a timely fashion, and to disseminate that essential knowledge in a comprehensible way to a greater scientific and clinical audience; as well as patients, caregivers, and drug and device manufacture, especially to support rare disease product development.

Publishing process

Book initiated and editor appointed

Date completed: November 26th 2020

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline Extended: Open for Submissions

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Approved chapters written in full and submitted

Deadline for full chapters: February 22nd 2021

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: May 13th 2021

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: July 12th 2021

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Mani T. Valarmathi

The University of Alabama at Birmingham

Mani T. Valarmathi is presently an assistant professor at the University of Alabama at Birmingham, USA. He began his scientific career as a cancer geneticist, but soon became captivated with the emerging and translational fields of stem cell biology, tissue engineering, and regenerative medicine. After completing his Bachelor’s degree in Chemistry at the University of Madras, he received his MBBS in Medicine and Surgery and MD in Pathology from the University of Madras, as well as his PhD in Medical Biotechnology from All-India Institute of Medical Sciences, New Delhi, India. For over 15 years, he has had extensive experience in research on various types of stem cells, including adult, embryonic (pluripotent), and induced pluripotent stem cells. Currently, his research work focuses on generating three-dimensional vascularized tissues and/or organs for implantation purposes. He is a member of many prestigious national and international professional societies and scientific organizations, such as ISSCR, TERMIS, AACR, ASIP, ACS, ESC, ISHR, ASGCT, and AHA.

View profile

Book chapters authored 2

Books edited 2

Introducing your Author Service Manager

Mrs. Mia Vulovic

As an Author Service Manager, my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question
creativecommons
alpsp
cope
stm
ithenticate
crossref
doi
oaspa

Book will be abstracted and indexed in

googlescholar
worldcat
base
az
openaire